Objectives: Gliomas and brain metastases (Mets) are the most common brain malignancies. The treatment strategy and clinical prognosis of patients are different, requiring accurate diagnosis of tumor types. However, the traditional radiomics diagnostic pipeline requires manual annotation and lacks integrated methods for segmentation and classification. To improve the diagnosis process, a gliomas and Mets computer-aided diagnosis method with automatic lesion segmentation and ensemble decision strategy on multi-center datasets was proposed.
Methods: Overall, 1,022 high-grade gliomas and 775 Mets patients' preoperative MR images were adopted in the study, including contrast-enhanced T1-weighted (T1-CE) and T2-fluid attenuated inversion recovery (T2-flair) sequences from three hospitals. Two segmentation models trained on the gliomas and Mets datasets, respectively, were used to automatically segment tumors. Multiple radiomics features were extracted after automatic segmentation. Several machine learning classifiers were used to measure the impact of feature selection methods. A weight soft voting (RSV) model and ensemble decision strategy based on prior knowledge (EDPK) were introduced in the radiomics pipeline. Accuracy, sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC) were used to evaluate the classification performance.
Results: The proposed pipeline improved the diagnosis of gliomas and Mets with ACC reaching 0.8950 and AUC reaching 0.9585 after automatic lesion segmentation, which was higher than those of the traditional radiomics pipeline (ACC:0.8850, AUC:0.9450).
Conclusion: The proposed model accurately classified gliomas and Mets patients using MRI radiomics. The novel pipeline showed great potential in diagnosing gliomas and Mets with high generalizability and interpretability.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576559 | PMC |
http://dx.doi.org/10.3389/fmed.2023.1232496 | DOI Listing |
J Ayub Med Coll Abbottabad
November 2024
Akbar Niazi Teaching Hospital, IMDC, Islamabad.
Clin Transl Oncol
October 2024
Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Objective: The purpose of this retrospective analysis was to evaluate the clinical presentations, radiological characteristics, patient outcomes, and therapeutic approaches among individuals diagnosed with primary central nervous system lymphoma (PCNSL), high-grade glioma (HGG), and metastatic brain tumors (METS).
Methods: We assembled a cohort of brain tumor patients from two medical centers, with two oncologists independently reviewing their clinical profiles. A retrospective examination of 87 PCNSL, 87 HGG, and 71 METS cases was performed to assess the aforementioned parameters.
Front Med (Lausanne)
September 2023
Academy for Engineering and Technology, Fudan University, Shanghai, China.
Objectives: Gliomas and brain metastases (Mets) are the most common brain malignancies. The treatment strategy and clinical prognosis of patients are different, requiring accurate diagnosis of tumor types. However, the traditional radiomics diagnostic pipeline requires manual annotation and lacks integrated methods for segmentation and classification.
View Article and Find Full Text PDFRadiol Case Rep
October 2023
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan.
Perilesional T1 hyperintensity on magnetic resonance imaging (MRI) of intra-axial brain masses is an unusual feature of the perilesional area, characteristic of cavernous malformations (CMs) and metastatic brain tumors (METs). Here, we report a case of primary diffuse glioma with a perilesional T1 hyperintense area (HIA) on MRI. A 61-year-old woman with transient aphasia visited our hospital.
View Article and Find Full Text PDFPLoS One
February 2021
Division of Radiology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!